Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Wednesday, 31 October 2012
- Alzheimer’s, cancer and rare disease research to benefit from landmark MRC-AstraZeneca compound collaboration The Medical Research Council (MRC) today announces £7 million of funding for 15 research projects
- Tuesday, 23 October 2012
- AstraZeneca and Ironwood announce linaclotide collaboration for China AstraZeneca and Ironwood Pharmaceuticals, Inc. announced today an agreement to co-develop and co-commercialise Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US Food and Drug Administration, in August, for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
- Monday, 8 October 2012
- AstraZeneca and Ardelyx announce worldwide licensing deal for NHE3 Inhibitor Programme for complications of renal disease, including diabetes-induced renal disease AstraZeneca and Ardelyx today announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme